That number is expected to rise as the population ages
Product Specifications The Body Pharm Retatrutide 64mg pen is a multi-dose subcutaneous injection device containing 64mg of lyophilised-then-solubilised retatrutide (LY3437943), a synthetic GIP/GLP-1/glucagon triple receptor agonist developed by Eli Lilly and currently in Phase 3 obesity trials [7][6]
What helps: Peppermint tea Ginger chews Small, frequent meals Light walking or stretching If symptoms are severe or prolonged, contact your provider
Safety Concerns and Liability Issues Like all pharmaceuticals, GLP-1 medications carry inherent safety challenges, including the risk of unanticipated adverse side effects
The Biology of Incretin Hormones
Back Unger, R, Orci, L (4 Jan 1975) 'The essential role of glucagon in the pathogenesis of diabetes mellitus', The Lancet , 305/7895, 14-16